Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright

Stoke Therapeutics (NASDAQ:STOK - Free Report) had its target price increased by HC Wainwright from $35.00 to $47.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Stoke Therapeutics' FY2025 earnings at ($2.68) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($1.65) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at $0.45 EPS.

Several other research firms also recently weighed in on STOK. Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Finally, Chardan Capital started coverage on Stoke Therapeutics in a research note on Friday, December 20th. They set a "buy" rating and a $24.00 price target on the stock. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $23.00.

Stoke Therapeutics Stock Performance

STOK stock traded down $0.41 on Tuesday, hitting $8.33. 1,043,541 shares of the company's stock were exchanged, compared to its average volume of 879,028. Stoke Therapeutics has a 12-month low of $5.21 and a 12-month high of $17.58. The firm has a 50 day moving average price of $10.62 and a two-hundred day moving average price of $12.32. The stock has a market cap of $441.24 million, a P/E ratio of -3.97 and a beta of 0.95.

Insider Buying and Selling

In related news, insider Barry Ticho sold 2,586 shares of the company's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $33,592.14. Following the completion of the transaction, the insider now owns 44,746 shares of the company's stock, valued at approximately $581,250.54. This represents a 5.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 9,696 shares of the company's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $123,914.88. Following the completion of the transaction, the general counsel now directly owns 35,142 shares of the company's stock, valued at $449,114.76. The trade was a 21.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Stoke Therapeutics by 123.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock valued at $1,053,000 after acquiring an additional 52,813 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Stoke Therapeutics by 6.7% during the fourth quarter. Squarepoint Ops LLC now owns 120,242 shares of the company's stock valued at $1,326,000 after acquiring an additional 7,575 shares during the last quarter. Tang Capital Management LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $3,309,000. Finally, RTW Investments LP raised its holdings in shares of Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after acquiring an additional 471,240 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.